Abstract:The basement membrane of skeletal muscle (myomatrix) consists of a complex network of highly glycosylated proteins. Important components of the myomatrix are the laminins and the collagens. During development, the myomatrix is assembled by interactions with cell surface receptors and by self-polymerization, which results in an extracellular scaffold important for skeletal muscle stability. Mutations in the α2 chain of laminin-211 impinge on myomatrix assembly and its interaction with cell surface receptors, and result in one of the most severe forms of congenital muscular dystrophy (MDC1A). Based on a detailed mechanistic understanding of the function of laminin-211, we have designed artificial linker molecules derived from agrin or perlecan with the aim to bridge the remaining myomatrix to cell surface receptors. In the conducted preclinical, proof-of-concept studies we were able to show that they can substantially ameliorate the disease phenotype in a mouse model of MDC1A. Subsequent approaches to further improve the treatment have focused on testing interventions that affect downstream pathways, such as apoptosis and inflammation, using pharmacological and genetic tools. All those treatments show additional beneficial effects on disease progression. However, semi-quantitative comparison of the treatments indicates that interventions that target early events in the disease are more efficacious than those targeting further downstream pathways. Finally, we will also report on the ongoing efforts to combine interventions that boost myomatrix assembly with those that connect it to skeletal muscle receptors. In summary, we will report on proof-of-concept studies that provide mechanistic insights and unequivocal preclinical evidence for the potential use of those therapies. As the MDC1A mice used in our studies share many hallmarks with the human disease, these preclinical data may be of high predictive value for future clinical studies. The basement membrane of skeletal muscle (myomatrix) consists of a complex network of highly glycosylated proteins. Important components of the myomatrix are the laminins and the collagens. During development, the myomatrix is assembled by interactions with cell surface receptors and by self-polymerization, which results in an extracellular scaffold important for skeletal muscle stability. Mutations in the α2 chain of laminin-211 impinge on myomatrix assembly and its interaction with cell surface receptors, and result in one of the most severe forms of congenital muscular dystrophy (MDC1A). Based on a detailed mechanistic understanding of the function of laminin-211, we have designed artificial linker molecules derived from agrin or perlecan with the aim to bridge the remaining myomatrix to cell surface receptors. In the conducted preclinical, proof-of-concept studies we were able to show that they can substantially ameliorate the disease phenotype in a mouse model of MDC1A. Subsequent approaches to further improve the treatment have focused on testing interventions that affect downstream pathways, such as apoptosis and inflammation, using pharmacological and genetic tools. All those treatments show additional beneficial effects on disease progression. However, semi-quantitative comparison of the treatments indicates that interventions that target early events in the disease are more efficacious than those targeting further downstream pathways. Finally, we will also report on the ongoing efforts to combine interventions that boost myomatrix assembly with those that connect it to skeletal muscle receptors. In summary, we will report on proof-of-concept studies that provide mechanistic insights and unequivocal preclinical evidence for the potential use of those therapies. As the MDC1A mice used in our studies share many hallmarks with the human disease, these preclinical data may be of high predictive value for future clinical studies.

Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin- 2-deficient mice

Linker Molecules Between Laminins and Dystroglycan Ameliorate Laminin-Alpha 2-Deficient Muscular Dystrophy at All Disease Stages

An Agrin Minigene Rescues Dystrophic Symptoms in a Mouse Model for Congenital Muscular Dystrophy

Apoptosis Inhibitors and Mini-Agrin Have Additive Benefits in Congenital Muscular Dystrophy Mice

G.P.212

Nerve Pathology is Prevented by Linker Proteins in Mouse Models for LAMA2-related Muscular Dystrophy.

Muscle-wide Secretion of a Miniaturized Form of Neural Agrin Rescues Focal Neuromuscular Innervation in Agrin Mutant Mice.

Linker Proteins Restore Basement Membrane and Correct LAMA2-related Muscular Dystrophy in Mice

Angiotensin II Type 1 Receptor Antagonists Alleviate Muscle Pathology in the Mouse Model for Laminin-Α2-deficient Congenital Muscular Dystrophy (MDC1A)

M.I.3 The role of laminins in myomatrix assembly and skeletal muscle stability

Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD

Increasing LRP4 diminishes neuromuscular deficits in a mouse model of Duchenne muscular dystrophy

Long-term Effect of Human Mini-Dystrophin in Transgenic Mdx Mice Improves Muscle Physiological Function.

Muscle-specific microRNA-206 targets multiple components in dystrophic skeletal muscle representing beneficial adaptations

Deficiency of skeletal muscle Agrin contributes to the pathogenesis of age-related sarcopenia in mice

The super-healing MRL strain promotes muscle growth in muscular dystrophy through a regenerative extracellular matrix

Suppression of myopathic lamin mutations by muscle-specific activation of AMPK and modulation of downstream signaling

Apelin stimulation of the vascular skeletal muscle stem cell niche enhances endogenous repair in dystrophic mice

A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene

Eliminating elevated p53 signaling fails to rescue skeletal muscle defects or extend survival in lamin A/C-deficient mice

37. Long-Term Expression of Mini-Human Dystrophin in Transgenic mdx Mice Improves Dystrophic Muscle Functions